Holen Sie sich die Stockscreener-App
37.01
0.75%
-0.28
Handel nachbörslich:
36.50
-0.51
-1.38%
Schlusskurs vom Vortag:
$37.29
Offen:
$37.43
24-Stunden-Volumen:
481.64K
Relative Volume:
0.97
Marktkapitalisierung:
$1.61B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-264.36
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
-4.93%
1M Leistung:
-4.69%
6M Leistung:
+37.23%
1J Leistung:
+63.83%
1-Tages-Spanne:
$36.78
$37.67
1-Wochen-Bereich:
$35.20
$42.05
52-Wochen-Spanne:
$17.82
$42.05
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
37.01 | 2.76B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat
Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com UK
New Strong Sell Stocks for Oct. 30th - The Globe and Mail
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha
Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates - sharewise.com
Kiniksa Pharmaceuticals International, plc SEC 10-Q Report - TradingView
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighHere's Why - MarketBeat
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction - Finimize
Key Developments in KNSA Revenue Forecasts - GuruFocus
KNSA Surpasses Revenue Expectations and Updates Sales Forecast - GuruFocus
Kiniksa Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Esti - GuruFocus
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results - TradingView
Kiniksa Pharma raises ARCALYST's 2025 sales forecast - MarketScreener
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals (NASDAQ: KNSA) raises ARCALYST net sales guidance to $670–$675M - Stock Titan
Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60 - Markets Mojo
Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KN - GuruFocus
Allspring Global Investments Holdings LLC Sells 29,796 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Michael Megna Sells 50,490 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 97,390 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 - The Manila Times
Kiniksa (Nasdaq: KNSA) sets Oct 28 8:30 a.m. ET webcast for third‑quarter results - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,524,862.87 in Stock - MarketBeat
Kiniksa Pharma CEO Patel sells $10 million in shares By Investing.com - Investing.com Nigeria
Kiniksa Pharma CEO Patel sells $10 million in shares - Investing.com India
Kiniksa Pharmaceuticals (KNSA): Investor Outlook on a 29% Upside Potential in the Biopharma Space - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High After Analyst Upgrade - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Citigroup Boosts Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $50.00 - Defense World
Cannon Global Investment Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment By Investing.com - Investing.com Canada
Eben Tessari Sells 12,368 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals (KNSA) Sees 11% Increase in Citigroup's Price Target | KNSA Stock News - GuruFocus
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment - Investing.com
Kiniksa (KNSA) Receives FDA Orphan Drug Status for Pericarditis Treatment - GuruFocus
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation - MarketScreener
Kiniksa Pharmaceuticals Receives Orphan Drug Designation from FDA for KPL-387 in Treating Pericarditis - Quiver Quantitative
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis - GlobeNewswire
Kiniksa Pharma COO Tessari sells $465,843 in shares By Investing.com - Investing.com Nigeria
KNSA Awarded FDA Orphan Designation for Pericarditis Treatment - GuruFocus
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - sharewise.com
Kiniksa Pharma COO Tessari sells $465,843 in shares - Investing.com India
Wedbush Issues Positive Forecast for KNSA Earnings - Defense World
Earnings call transcript: Kiniksa Pharmaceuticals sees strong Q2 2025 growth By Investing.com - Investing.com UK
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.18%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):